Decimal Point - Osteoporosis Therapy at the 10-Year Mark

New England Journal of Medicine

Volumn 350, Issue 12, 2004, Pages 1172-1174

  Strewler, Gordon J ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; PARATHYROID HORMONE[1-34]; RALOXIFENE; RISEDRONIC ACID; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

BONE MASS; BONE MINERALIZATION; BONE TURNOVER; HIGH RISK POPULATION; HIP FRACTURE; LUMBAR SPINE; OSSIFICATION; OSTEOLYSIS; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW;

ALENDRONATE; BONE DENSITY; BONE REMODELING; DIPHOSPHONATES; FEMALE; FRACTURES, BONE; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; TIME FACTORS;

EID: 1542615159     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMp048017     Document Type: Review

References (5)

1. Meunier PJ, Roux C, Seeman E, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004;350:459-68.
2. Tucci JR, Tonino RP, Emkey RD, Peverly CA, Kher U, Santora AC II. Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis. Am J Med 1996;101:488-501.
3. Devogelaer JP, Broll H, Correa-Rotter R, et al. Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis. Bone 1996;18:141-50. [Erratum, Bone 1996;19:78.]
4. Devogelaer JP, Broll H, Correa-Rotter R, et al. Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis. Bone 1996;18:141-50. [Erratum, Bone 1996;19:78.]
5. Liberman UA, Weiss SR, Broll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995;333:1437-43.